Company news
CNBX Pharmaceuticals Inc. news in 2020
CNBX Pharmaceuticals Inc.'s news releases, calls and decks from 2020, newest first.
Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package
December 21, 2020
Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors
November 16, 2020
Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33
November 9, 2020
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application
October 27, 2020
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33
October 21, 2020
Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33
August 20, 2020
Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors
August 5, 2020
Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets
July 14, 2020
Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors
June 16, 2020
Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers
June 10, 2020
Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis
May 26, 2020
Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids
May 6, 2020
Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors
April 27, 2020
Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer
April 13, 2020
Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids
March 25, 2020
Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research
March 18, 2020
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma
March 11, 2020
Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells
March 2, 2020
Cannabics Pharmaceuticals Partners With NewCanna to Commence Research Based on Colombian Indigenous Cannabis Landraces
February 25, 2020
Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form
February 18, 2020
Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers
February 11, 2020
Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit
January 27, 2020
Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties
January 9, 2020